We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical's Record Cash Flow Gives It an Innovation Advantage
Read MoreHide Full Article
Key Takeaways
ISRG's first-half 2026 free cash flow surged 71% to $1.8B, while cash and investments hit $8.6B.
ISRG is growing R&D faster than SG&A and plans more than 100 updates for the da Vinci 5 platform.
ISRG is advancing a flexible robotic GI endoscope and investing across AI, robotics, imaging and materials.
Intuitive Surgical's (ISRG - Free Report) surging cash generation is giving it a meaningful competitive edge as the robotic surgery leader doubles down on innovation. First-half 2026 free cash flow jumped 71% year over year to $1.8 billion, while cash and investments reached $8.6 billion, providing ample financial flexibility to fund research, manufacturing expansion and shareholder returns without compromising growth initiatives.
Management is using that financial strength to widen its technology moat. ISRG is intentionally growing R&D faster than SG&A, expanding manufacturing capacity with new hiring and facility investments, and rolling out more than 100 planned updates for the da Vinci 5 platform. The company is also advancing next-generation programs, including a flexible robotic GI endoscope, while supporting innovation across AI, robotics, imaging and advanced materials. Alongside these investments, ISRG repurchased $379 million of stock during the quarter, underscoring confidence in its long-term outlook.
Peers Update
Boston Scientific (BSX - Free Report) delivered another solid quarter, with second-quarter 2026 revenues rising 7.5% to $5.44 billion and adjusted EPS climbing 15% to 86 cents. Growth was driven by strength across Interventional Cardiology, Neuromodulation and Vascular businesses, while the company continued investing in future platforms, including SEISMIQ IVL, hypertension therapies and FARAWAVE Ultra. However, management trimmed its full-year outlook as WATCHMAN and electrophysiology pressures weighed on near-term expectations.
Medtronic (MDT - Free Report) continues strengthening its electrophysiology franchise through innovation. The company secured an expanded CE Mark for the Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, making it the first all-in-one mapping and ablation, dual-energy catheter approved in Europe for ventricular ablation. Medtronic also received FDA Breakthrough Device Designation for the technology, while its U.S. Sphere VT pivotal trial is enrolling patients, positioning the platform for future market expansion in a fast-growing cardiac ablation segment.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 34.6% in the year-to-date period compared with the industry’s decline of 6.9%.
Image Source: Zacks Investment Research
From a valuation standpoint, ISRG trades at a price-to-book ratio of 7.15, above the industry average. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ISRG’s 2026 earnings implies a significant 20.3% improvement from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Intuitive Surgical's Record Cash Flow Gives It an Innovation Advantage
Key Takeaways
Intuitive Surgical's (ISRG - Free Report) surging cash generation is giving it a meaningful competitive edge as the robotic surgery leader doubles down on innovation. First-half 2026 free cash flow jumped 71% year over year to $1.8 billion, while cash and investments reached $8.6 billion, providing ample financial flexibility to fund research, manufacturing expansion and shareholder returns without compromising growth initiatives.
Management is using that financial strength to widen its technology moat. ISRG is intentionally growing R&D faster than SG&A, expanding manufacturing capacity with new hiring and facility investments, and rolling out more than 100 planned updates for the da Vinci 5 platform. The company is also advancing next-generation programs, including a flexible robotic GI endoscope, while supporting innovation across AI, robotics, imaging and advanced materials. Alongside these investments, ISRG repurchased $379 million of stock during the quarter, underscoring confidence in its long-term outlook.
Peers Update
Boston Scientific (BSX - Free Report) delivered another solid quarter, with second-quarter 2026 revenues rising 7.5% to $5.44 billion and adjusted EPS climbing 15% to 86 cents. Growth was driven by strength across Interventional Cardiology, Neuromodulation and Vascular businesses, while the company continued investing in future platforms, including SEISMIQ IVL, hypertension therapies and FARAWAVE Ultra. However, management trimmed its full-year outlook as WATCHMAN and electrophysiology pressures weighed on near-term expectations.
Medtronic (MDT - Free Report) continues strengthening its electrophysiology franchise through innovation. The company secured an expanded CE Mark for the Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, making it the first all-in-one mapping and ablation, dual-energy catheter approved in Europe for ventricular ablation. Medtronic also received FDA Breakthrough Device Designation for the technology, while its U.S. Sphere VT pivotal trial is enrolling patients, positioning the platform for future market expansion in a fast-growing cardiac ablation segment.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 34.6% in the year-to-date period compared with the industry’s decline of 6.9%.
Image Source: Zacks Investment Research
From a valuation standpoint, ISRG trades at a price-to-book ratio of 7.15, above the industry average. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ISRG’s 2026 earnings implies a significant 20.3% improvement from the year-ago period.
Image Source: Zacks Investment Research
The company currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.